Policy & Regulation
Sage Therapeutics Names Benecchi as Chief Commercial Officer
21 September 2021 - - US-based biopharmaceutical company Sage Therapeutics (NASDAQ: SAGE) has appointed Chris Benecchi as chief commercial officer, the company said.

In his new role, Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence.

Benecchi will work in collaboration with internal partners to create a shared, mission-driven, launch vision that reflects the input the company receives from external stakeholders.

Among his responsibilities will be to ensure smooth working relationships with Sage's partners and an integrated commercialization plan for zuranolone a once-daily, two-week therapy in Phase 3 clinical development for the treatment of major depressive disorder and postpartum depression.

Benecchi will also lead commercialization strategies across the company's leading portfolio of treatments for brain health disorders.

Chris Benecchi joins Sage from Alexion, where he served as vice president, Global Head of Commercial Excellence.

Previously, he spent eight years at UCB in commercial roles of increasing responsibility including Global Launch Head, Commercial and Medical Affairs, Immunology and Global Commercial Strategy Lead, Immunology.

He began his career in sales at J and J and held sales leadership and senior marketing roles at Takeda as well. Benecchi received an MBA from Duke University and a BA from Colby College.

Sage Therapeutics is a biopharmaceutical company focused on developing novel therapies for patients with debilitating disorders of the brain.